PIRTOBRUTINIB IN COVALENT BTK-INHIBITOR PRE-TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS AND SUBGROUP ANALYSIS FROM THE PHASE 1/2 BRUIN STUDY WITH 2 YEARS OF SURVIVAL FOLLOW-UP
Objectives: Pirtobrutinib is a highly selective, non-covalent (reversible) BTK-inhibitor (BTKi). Here, we report updated results of pirtobrutinib in patients (pts) with cBTKi pre-treated relapsed/refractory (R/R) mantle cell lymphoma (MCL) and more than 3 years follow-up from start of enrollment. Ma...
Uloženo v:
| Hlavní autoři: | , , , , , , , , , |
|---|---|
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
Elsevier
2023-10-01
|
| Edice: | Hematology, Transfusion and Cell Therapy |
| On-line přístup: | http://www.sciencedirect.com/science/article/pii/S2531137923008672 |
| Tagy: |
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|